Indian medical innovation is over again in glare of publicity in biotechnology sector as a leader in stem cell therapy and the credit goes to Dr Geeta Shroff, Founder and Medical Director, Nutech Mediworld in being granted 66th patent on ground breaking human embryonic stem cell technology to treat incurable diseases in Malaysia. Earlier in 2015, Dr Shroff’s technology was officially granted its 65th patent in Israel and the technology has already been granted patents in countries like Japan, Singapore, South Korea, USA, Australia and New Zealand. It is worth mentioning here that the incredible team has an additional 82 patents in different countries at varying stages of evaluation. Dr. Shroff, an infertility expert in in-vitro fertilization (IVF), initiated her research on human embryonic stem cells in 1999 and is regarded as a global pioneer in human embryonic stem cell therapy. She has been the first to develop purely human embryonic stem cell lines using just a single, spare, pre-implantation stage fertilized egg from a regular IVF cycle. The same original embryonic stem cell line, which was established as a result of a patient donation in Dr. Geeta’s IVF work in 2000, is still being used today, without any replication of fertilized eggs. The technology is commonly employed for treatment of many incurable diseases ranging from spinal cord injury, diabetes, ALS, cerebral palsy, stroke, Parkinson’s disease, multiple sclerosis, Lyme disease, autism and others. The patented technology is discriminated from other stem cell therapies in three major ways like, universal application, availability in a ready-to-use form with a shelf life of six months without any need for sophisticated transportation, and an easy non-invasive delivery mechanism in the simple form of an injection. Dr. Geeta considers making this therapy available globally, in the form of first line of treatment for conditions presently labeled as incurable or terminal.